NIH to test Lilly’s Covid-19 antibody
Tony Fauci wore a face mask emblazoned with monoclonal antibodies to a press call announcing the first of a series of U.S. government trials aimed at testing experimental drugs as treatments for Covid-19.
The study will test the monoclonal antibody developed by Eli Lilly, the Indianapolis drug giant, and Abcellera, a Vancouver, British Columbia biotech, in 220 volunteers who have symptoms and test positive for SARS-CoV-2 but are not hospitalized. Half will receive the treatment, and half a saline placebo. They’ll be tracked to see how fast their viral levels drop, and to see whether they maintain healthy levels of oxygen in their blood, among other measures. If the results are positive, the study will expand and measure more rigorous endpoints, and could eventually be used for approval.
The antibody was originally isolated from samples taken from a patient at the National Institute for Allergy and Infectious Diseases, which Fauci runs, by Abcellera. It is one of several antibodies in development. On Monday, Lilly announced the same antibody would be tested at nursing homes to try to prevent infection. An antibody cocktail from Regeneron is also being tested for prevention, in patients who are not hospitalized, and in those who are.
The study will test the monoclonal antibody developed by Eli Lilly, the Indianapolis drug giant, and Abcellera, a Vancouver, British Columbia biotech, in 220 volunteers who have symptoms and test positive for SARS-CoV-2 but are not hospitalized. Half will receive the treatment, and half a saline placebo. They’ll be tracked to see how fast their viral levels drop, and to see whether they maintain healthy levels of oxygen in their blood, among other measures. If the results are positive, the study will expand and measure more rigorous endpoints, and could eventually be used for approval.
The antibody was originally isolated from samples taken from a patient at the National Institute for Allergy and Infectious Diseases, which Fauci runs, by Abcellera. It is one of several antibodies in development. On Monday, Lilly announced the same antibody would be tested at nursing homes to try to prevent infection. An antibody cocktail from Regeneron is also being tested for prevention, in patients who are not hospitalized, and in those who are.
No hay comentarios:
Publicar un comentario